🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Par Drugs and Chemicals Limited PAR NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.pardrugs.com
Company Profile ↓
₹104.60
+1.45% 1Y
Mkt Cap₹128.71 Cr
P/E9.82
P/B1.29
52W High₹168.25
52W Low₹78.58
Book Value₹90.52
EPS (TTM)₹10.65

Company Overview

Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, magnesium aluminometasilicate, magnesium aluminosilicate-USP, magnesium oxide light, magnesium oxide heavy, magnesium aluminium hydrate, hydrotalcite, and synthetic aluminium silicate. It offers fine chemicals, such as precipitated silica, sodium aluminium silicate, amorphous aluminium hydroxide, Alusil, PARSIL-HT, aluminium hydroxide magnesium carbonate co-dried gel, magnesium aluminium silicate hydrated (pharma), and magnesium aluminium silicate hydrated (agro). Par Drugs and Chemicals Limited was founded in 1982 and is based in Vadodara, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 15.1%.

Reasonable Valuation

Trades at a P/E of 9.8, below the sector median of 35.9.

Healthy Margins

Operating margin of 17.3% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.00.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹103.66 Cr (+2.7% YoY); net profit ₹13.11 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +20.1%, earnings +41.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 2.9%, profit CAGR 5.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:2.91%
1 Year:20.10%

Compounded Profit Growth

5 Years:4.97%
1 Year:41.90%

Stock Price Performance

1 Year:+1.45%
6 Months:+14.78%
3 Months:+8.75%
1 Month:-20.91%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 29% of range
₹78.58 ₹168.25
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)32.05 · Neutral
Price Performance
1M-20.91%
3M+8.75%
6M+14.78%
1Y+1.45%
Valuation vs Sector

P/E of 9.82 is below the sector median of 35.90 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 37.8% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
9.82
Industry PE
35.90
Forward P/E est.
6.92
PEG Ratio
-
Book Value
₹90.52
Price to Book
1.29
P/S
1.32
EV/EBITDA
5.41
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
2.91%
Profit 5Y
4.97%
Revenue (YoY)
20.10%
Earnings (YoY)
41.90%

Profitability & Returns

ROCE
15.09%
ROE
11.71%
ROA
10.15%
Profit Margin
13.31%
Op Margin
17.32%
Gross Margin
57.97%
EPS (Latest Qtr)
₹0.69
EPS (TTM)
₹10.65

Balance Sheet & Liquidity

Debt/Equity
0.00
Quick Ratio
4.29
Current Ratio
4.68
Debt
₹0
Total Assets
₹129.21 Cr
Current Assets
₹64.33 Cr
Working Capital
₹50.58 Cr

Ownership

Promoter Holding
-
Chg in Prom Hold
-
FII / Inst Holding
-
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹128.71 Cr
Total Revenue (TTM)
₹108.89 Cr
EBITDA
₹19.90 Cr
Free Cash Flow
₹14.47 Cr
Operating Cash Flow
₹16.43 Cr
Shares Outstanding
₹1.23 Cr
Gross Margin
57.97%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PAR Par Drugs and Chemicals Limited NSEPHARMA 104.60 9.82 ₹128.71 Cr 0.00% 15.09% 11.71% 2.91% 4.97%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,758.00 34.88 ₹4.22 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,162.00 83.32 ₹2.43 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,615.30 73.73 ₹1.76 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,135.00 25.30 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 634.25 165.17 ₹1.10 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,604.50 52.35 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,002.50 98.99 ₹1.08 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,330.90 31.92 ₹1.08 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 22.33 Cr26.05 Cr28.66 Cr29.34 Cr19.61 Cr
Cost of Revenue 9.78 Cr11.34 Cr10.72 Cr12.39 Cr8.91 Cr
Gross Profit 12.55 Cr14.71 Cr17.94 Cr16.95 Cr10.70 Cr
Operating Expenses 11.04 Cr12.05 Cr12.81 Cr11.81 Cr10.19 Cr
Operating Income 1.51 Cr2.66 Cr5.12 Cr5.13 Cr51.44 L
EBITDA 3.22 Cr5.40 Cr6.55 Cr7.39 Cr1.80 Cr
Interest Expense 1.87 L1.63 L5.49 L1.48 L4.14 L
Pretax Income 2.28 Cr4.48 Cr5.55 Cr6.44 Cr83.15 L
Tax Provision 62.77 L1.15 Cr1.42 Cr1.64 Cr-2.21 L
Net Income 1.65 Cr3.33 Cr4.13 Cr4.80 Cr85.36 L
Diluted EPS 1.342.703.363.900.69

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -95.10 Cr95.11 Cr100.97 Cr103.66 Cr
Cost of Revenue -66.40 Cr58.88 Cr38.13 Cr43.36 Cr
Gross Profit -28.69 Cr36.22 Cr62.84 Cr60.29 Cr
Operating Expenses -14.13 Cr16.06 Cr46.99 Cr46.87 Cr
Operating Income -14.56 Cr20.16 Cr15.85 Cr13.43 Cr
EBITDA -18.31 Cr22.95 Cr21.65 Cr21.13 Cr
Interest Expense -24,00008.21 L12.73 L
Pretax Income -15.08 Cr19.52 Cr17.92 Cr17.30 Cr
Tax Provision -3.75 Cr5.02 Cr4.57 Cr4.19 Cr
Net Income -11.33 Cr14.50 Cr13.36 Cr13.11 Cr
Diluted EPS 7.499.2111.7810.86-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -88.87 Cr101.61 Cr119.39 Cr129.21 Cr
Current Assets -49.44 Cr59.62 Cr54.86 Cr64.33 Cr
Cash & Equivalents -22.24 Cr36.65 Cr27.58 Cr41.84 Cr
Inventory -5.38 Cr4.18 Cr6.11 Cr5.37 Cr
Receivables -16.97 Cr13.71 Cr16.71 Cr12.03 Cr
Total Liabilities -17.63 Cr15.98 Cr20.42 Cr17.23 Cr
Current Liabilities -13.99 Cr12.44 Cr16.57 Cr13.74 Cr
Long Term Debt -0000
Total Debt -0000
Total Equity -71.24 Cr85.63 Cr98.97 Cr111.98 Cr
Shares Outstanding -1.23 Cr1.23 Cr1.23 Cr1.23 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -13.38 Cr20.25 Cr16.16 Cr16.43 Cr
Investing Cash Flow --7.34 Cr-5.84 Cr-25.24 Cr-2.17 Cr
Financing Cash Flow --24,000000
Capital Expenditure --7.63 Cr-6.08 Cr-1.23 Cr-1.96 Cr
Free Cash Flow -5.74 Cr14.17 Cr14.93 Cr14.47 Cr
Net Change in Cash -6.04 Cr14.41 Cr-9.08 Cr14.27 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -30.2%38.1%62.2%58.2%
Operating Margin % -15.3%21.2%15.7%13.0%
Net Margin % -11.9%15.2%13.2%12.6%
ROE % -15.9%16.9%13.5%11.7%
ROCE % -19.4%22.6%15.4%11.6%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PAR

Google News Wed, 21 Oct 2026

Par Pacific Holdings, Inc. (PARR) Stock Price, News, Quote & History - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE9tdjFZcEZndDl3cTJKU1lhakRJLVlVS1JvbmRQUmVIYjJuWmV6R0tCVUUwdUY5S1lZN0ExZVlmQTVCY3BqZEVZTzNDT1NzYkthVVE?oc=5" target="_blank">Par Pacific Holdings, Inc. (PARR) Stock Price, News, Quo…

Google News hu, 24 Sep 2026

Stocks Climb Back To Par - WSJ

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFA1Vm1TVFlWRkk3eHhUcThlb3J6NVo1U3BkMWRKdGdpLVhsVzVveUhSM3pobTBmMnZvLTJvQlN0TXlYRkxKRkJKR1pua09CMTZVc1BfMDZWeWJJLW11WHQtUWpFNXJvQUtndjltX2NoRFpZWG5ZWFk4?oc=5" target="_blank">Stocks …

Google News Fri, 23 Oct 2026

Assenagon Asset Management S.A. Acquires New Shares in PAR Technology Corporation $PAR - MarketBeat

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNWnc4ZlEzQ3ZHZzZFNVNmZWZjeVhpYnlYX19zb1dxYnlkV0pmOTl5UzdIUzNhc3ZlUUdEVXJUMVEzUzRXb01PRkRFWFJvUmJ1bkNvc3NIM3RRdkNQYXRwQ0w2WF95bldub3dQWFpSYnhFRTh3WTVJVHhiWDQzdVM5QzZUZi16WVkzNldqTE…

Google News Mon, 09 Mar 2026

Par Tech faces investor pressure - Payments Dive

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE80ZHR3dF9WeVNYSk1iQnktdU9wNnc2bU84NTFzbmRZZk5xbjI4WW5VdTZJeWpYWENQemFGUGxuTkVYSHkzMEVpeGxFdnYzd0tQVDlPamd1VUlRNlN5cHJlWGRtaUxUVlM2X084VmxIdVBLOWJVeW9zRF92TGdRX2M?oc=5" target="_bla…

Google News Fri, 29 May 2026

Why PAR Technology (PAR) Shares Are Trading Lower Today - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPX25mZnVzX1NPODRaYWZMVkN6aEZfMzJCYlZtNVJEMVJRUGNfNWtlZkFkbHUybzByVkRCQlZlU0xWNGJCcnROUlByQ0lFcHpZNTBqd0QxTkllWkNUZWs4VFU0S2dFSE1CS0V4Y2pPc0tFc212eFVaQzJUaEp6a2Z1czdOcWpkT1EwWVZnc1…

Google News hu, 22 Oct 2026

PAR Technology (NYSE:PAR) Shares Break Above Two Hundred Day Moving Average - Here's What Happened - MarketBeat

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxOU091TzRGUjBGWDNzMHlqdFFjdzNvTjFseW9sRG5iampVU3dlaXk4N3RpMENwN1hzZUp2UHFqYmVMQk9kZC1GTzVlcW1yRHNZME1tRFRXaENjdFc5Z2RvWWYxWS1JLW50VXhZR08wbTh6X0pJNlRFN285TVRuUGlTczBxYk1VOEotd2JnTG…

PAR — Frequently Asked Questions

What is the current share price of Par Drugs and Chemicals Limited (PAR)?

As of 2026-10-24 04:55 IST, Par Drugs and Chemicals Limited (PAR) trades at ₹104.60 on NSE. Its 52-week range is ₹78.58 to ₹168.25.

What is the market capitalisation of PAR?

Par Drugs and Chemicals Limited (PAR) has a market capitalisation of ₹128.71 Cr on NSE.

What is the P/E ratio of PAR?

PAR trades at a trailing price-to-earnings (P/E) ratio of 9.82. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 1.29.

What is the return on equity (ROE) of PAR?

PAR has a return on equity (ROE) of 11.71%. Its return on capital employed (ROCE) is 15.09%.

Is PAR a good stock to buy?

This page provides a data-driven analysis of Par Drugs and Chemicals Limited (PAR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space